JACC. Cardiovascular interventions最新文献

{"title":"OCT-Guided PCI in Diabetes","authors":"José M. de la Torre-Hernández MD, PhD","doi":"10.1016/j.jcin.2026.07.013","DOIUrl":"10.1016/j.jcin.2026.07.013","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2360-2363"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual‑Imaging Biopsy With Angioscopy and Intracardiac Echocardiography for Cardiac Metastatic Squamous Cell Carcinoma","authors":"Toru Yoshizaki MD, PhD, Katsuya Miyahara MD, Takeaki Goto MD, Daichi Inomata MD, Akira Sato MD, PhD","doi":"10.1016/j.jcin.2026.06.031","DOIUrl":"10.1016/j.jcin.2026.06.031","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Pages 2421-2424"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EuroTR Risk Score","authors":"Julien Dreyfus MD, PhD, David Messika-Zeitoun MD, PhD","doi":"10.1016/j.jcin.2026.04.057","DOIUrl":"10.1016/j.jcin.2026.04.057","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 17","pages":"Page 2425"},"PeriodicalIF":12.7,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148961790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Best Practices for Intravascular Ultrasound-Based Coronary Bifurcation Segmentation.","authors":"Soo-Jin Kang, Akiko Maehara, Mitsuaki Matsumura, Ernest Spitzer, Joost Daemen, Hector M Garcia-Garcia, Yirga Kahsay, Daniel Chamie, Jihoon Kweon, Gary S Mintz","doi":"10.1016/j.jcin.2026.07.017","DOIUrl":"https://doi.org/10.1016/j.jcin.2026.07.017","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":12.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves.","authors":"Raj R Makkar, Wen Cheng, Ron Waksman, Tarun Chakravarty, Lowell F Satler, Mark Groh, William Abernethy, Mark J Russo, David Heimansohn, James Hermiller, Stephen Worthley, Bassem M Chehab, Ray Matthews, Ravi K Ramana, Gerald Yong, Chunguang Chen, Federico M Asch, Mamoo Nakamura, Hasan Jilaihawi, Rahul Sharma, Dhairya Patel, Samir Kapadia, Michael J Reardon, Deepak L Bhatt, Gregory P Fontana","doi":"10.1016/j.jcin.2026.05.032","DOIUrl":"https://doi.org/10.1016/j.jcin.2026.05.032","url":null,"abstract":"<p><strong>Background: </strong>Long-term outcomes of the self-expanding intra-annular Portico transcatheter aortic valve are not known.</p><p><strong>Objectives: </strong>This study aimed to report the 5-year outcomes of the PORTICO IDE randomized controlled trial.</p><p><strong>Methods: </strong>This multicenter trial randomized (1:1) patients with severe symptomatic aortic stenosis at high/extreme surgical risk to transcatheter aortic valve replacement (TAVR) with the self-expanding intra-annular valve (study valve) or Food and Drug Administration-approved commercially available valves (CAVs; balloon-expandable or self-expanding supra-annular platforms). Assessments of the primary safety endpoint (30 days) and the primary efficacy endpoint (1 year) have been previously reported. Prespecified clinical outcomes and hemodynamic valve parameters are presented through 5 years.</p><p><strong>Results: </strong>We randomized 750 eligible patients (mean age: 83 years, 52.7% female) to the study valve (n = 381) or CAV (n = 369). Compared with CAV, the study valve showed similar 5-year all-cause mortality or stroke (55.6% vs 51.3%, P = 0.42). Cardiovascular mortality was numerically higher in the study valve group compared with the CAV group (33.4% vs 25.8%; P = 0.06). Naïve permanent pacemaker implantation was higher in the study valve group (36.6%) than the CAV group (20.3%; P < 0.0001) at 5 years. At 5 years, the study valve showed a lower mean transvalvular gradient (7.2 ± 3.0 vs 9.5 ± 6.5 mm Hg, P = 0.008), but similar valve area (1.78 ± 0.45 vs 1.71 ± 0.51 cm², P = 0.40) compared to CAV.</p><p><strong>Conclusions: </strong>In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.</p>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":12.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Tricuspid Valve Stability Beyond Leaflet Capture: When Annular Compression Compensates for Incomplete Anchoring.","authors":"Ahmad Hayek, Anissa Bouali, Marco Vola, Brahim Harbaoui","doi":"10.1016/j.jcin.2026.07.018","DOIUrl":"https://doi.org/10.1016/j.jcin.2026.07.018","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":" ","pages":""},"PeriodicalIF":12.7,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The SIRONA Study","authors":"Yann Gouëffic MD, PhD,&nbsp;Tom Le Corvec MD, PhD","doi":"10.1016/j.jcin.2026.07.005","DOIUrl":"10.1016/j.jcin.2026.07.005","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 16","pages":"Pages 2262-2264"},"PeriodicalIF":12.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148806979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redo-TAVR (TAV-in-TAV) Best Practices Part 2: Tall-in-Short and Tall-in-Tall","authors":"Vinayak N. Bapat MBBS,&nbsp;Syed Zaid MD,&nbsp;Miho Fukui MD, PhD,&nbsp;Steven J. Yakubov MD,&nbsp;Pradeep Yadav MD,&nbsp;Mathew R. Williams MD,&nbsp;John G. Webb MD,&nbsp;Nicolas Van Mieghem MD, PhD,&nbsp;Didier Tchétché MD,&nbsp;Giuseppe Tarantini MD, PhD,&nbsp;Ana Paula Tagliari MD, PhD,&nbsp;Curtiss T. Stinis MD,&nbsp;Cezar S. Staniloae MD,&nbsp;Stephanie L. Sellers PhD,&nbsp;Toby Rogers MD, PhD,&nbsp;Grant W. Reed MD,&nbsp;Basel Ramlawi MD,&nbsp;Karl Poon MD,&nbsp;Radoslaw Parma MD, PhD,&nbsp;Yohei Ohno MD, PhD,&nbsp;Gilbert H.L. Tang MD, MSc, MBA","doi":"10.1016/j.jcin.2026.06.004","DOIUrl":"10.1016/j.jcin.2026.06.004","url":null,"abstract":"<div><div>Transcatheter aortic valve replacement (TAVR) has created a growing population of patients who require redo-TAVR (TAV-in-TAV) for structural valve deterioration. Tall-frame self-expanding valves implanted within failed short- or tall-frame transcatheter valves (“tall-in-short” and “tall-in-tall”) present distinct challenges related to anchoring, constrained expansion, valve alignment, and the risk for coronary obstruction or sinus sequestration driven by the resulting neoskirt plane. Under the auspices of the Heart and Valve Collaboratory, an international multidisciplinary panel reviewed bench and clinical data and synthesized contemporary best practices into a pragmatic procedural workflow for redo-TAVR in these settings. This consensus document standardizes key definitions, outlines computed tomography–based strategies for in vivo sizing and risk stratification, and details recommended approaches to predilatation, deployment technique, postdilatation, coronary protection and leaflet modification, or hybrid surgical alternative when needed. A structured troubleshooting guide is provided to support safe, reproducible execution and coronary preservation.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 16","pages":"Pages 2165-2191"},"PeriodicalIF":12.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148304934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-Human Experience With a Novel Pressure-Controlled, Flow-Regulating Extracorporeal Limb Perfusion Device","authors":"Christian Said MBBS, MSc,&nbsp;Peter Natov MD,&nbsp;Khurshid Fozilov MBBS,&nbsp;Sharipov Islamjon MBBS,&nbsp;Adkhamjon Khakimov MD,&nbsp;Dzmitry V. Turliuk MBBS,&nbsp;Nikita Konovalov MD,&nbsp;John McCarthy MEng,&nbsp;Mano Iyer MSME, MBA,&nbsp;Peter A. Schneider MD,&nbsp;Imran Aslam MD,&nbsp;Navin K. Kapur MD","doi":"10.1016/j.jcin.2026.06.019","DOIUrl":"10.1016/j.jcin.2026.06.019","url":null,"abstract":"","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 16","pages":"Pages 2271-2273"},"PeriodicalIF":12.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148806912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redo–Transcatheter Aortic Valve Replacement With Self-Expanding Valves","authors":"Toby Rogers MD,&nbsp;Vinayak N. Bapat MD,&nbsp;Stanley J. Chetcuti MD,&nbsp;Harold L. Dauerman MD,&nbsp;John K. Forrest MD,&nbsp;Sachin S. Goel MD,&nbsp;Kendra J. Grubb MD,&nbsp;Wah Wah Htun MD,&nbsp;Rishi Puri MD,&nbsp;Michael J. Reardon MD,&nbsp;Gilbert H.L. Tang MD, MSc, MBA,&nbsp;Amit N. Vora MD,&nbsp;Steven J. Yakubov MD,&nbsp;Ruth Eisenberg MSc,&nbsp;Guilherme F. Attizzani MD","doi":"10.1016/j.jcin.2026.07.009","DOIUrl":"10.1016/j.jcin.2026.07.009","url":null,"abstract":"<div><h3>Background</h3><div>Redo–transcatheter aortic valve replacement (TAVR) for failed transcatheter heart valves is expected to increase, but data on outcomes with self-expanding valves remain limited.</div></div><div><h3>Objectives</h3><div>The aims of this study were to evaluate procedural, clinical, and quality-of-life outcomes following redo-TAVR using self-expanding Evolut valves and to compare these outcomes with those among a contemporary native TAVR cohort.</div></div><div><h3>Methods</h3><div>Outcomes after redo-TAVR with Evolut R, Evolut PRO, and Evolut PRO+ valves in the Society of Thoracic Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry were analyzed and compared with outcomes after native-valve TAVR using the same valve platform during the same study period. The primary endpoints were all-cause mortality, stroke, and readmission at 30 days and 1 year.</div></div><div><h3>Results</h3><div>Among 439 redo-TAVR patients (mean age 78.9 ± 9.8 years, 63.1% women), procedural complication rates were low. Redo-TAVR reduced transvalvular gradients at 1 year, although gradients remained modestly higher than after native TAVR (11.3 ± 6.1 mm Hg vs 8.2 ± 4.6 mm Hg; <em>P</em> &lt; 0.001). After adjustment, clinical outcomes were similar between redo-TAVR and native TAVR at 30 days (mortality adjusted HR: 0.66 [95% CI: 0.39-1.13; <em>P</em> = 0.129]; stroke adjusted HR: 0.95 [95% CI: 0.54-1.68; <em>P</em> = 0.853]; readmission adjusted HR: 0.88 [95% CI: 0.65-1.20; <em>P</em> = 0.422]) and 1-year (mortality adjusted HR: 0.91 [95% CI: 0.72-1.15; <em>P</em> = 0.441]; stroke adjusted HR: 0.91 [95% CI: 0.63-1.34; <em>P</em> = 0.644]; readmission adjusted HR: 0.92 [95% CI: 0.76-1.13; <em>P</em> = 0.439]). Improvements in functional status and quality of life were observed early after redo-TAVR and were sustained through 1 year. Findings were consistent across prespecified subgroups.</div></div><div><h3>Conclusions</h3><div>In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR. These findings support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.</div></div>","PeriodicalId":14688,"journal":{"name":"JACC. Cardiovascular interventions","volume":"19 16","pages":"Pages 2204-2216"},"PeriodicalIF":12.7,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148806973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}